ERS and the patents
ERS Genomics was co-founded by Dr. Emmanuelle Charpentier to provide broad access to the fundamental CRISPR/Cas9 patent estate.
For more information on licensing, click here:
What do the CVC patents cover?
In Europe the CVC inventors have been awarded three broad patents on the CRISPR/Cas9 technology that include claims to the following:
- A composition comprising a chimeric Cas9 protein and a DNA targeting RNA which includes a DNA-targeting segment and a protein-binding segment comprising tracrRNA and CRISPR RNA (crRNA)
- A method of modifying a target DNA in a single-cell eukaryotic organism, an animal cell, or a plant cell comprising contacting the target DNA with a CRISPR/Cas9 complex
- A method of modifying a target DNA comprising contacting the target DNA with a CRISPR/Cas9 complex where the crRNA and tracrRNA are covalently linked by intervening nucleotides (single guide RNA)
In the USA the CVC portfolio currently contains 37 issued or allowed and 37 pending patents which include claims to the following:
- Compositions and methods of using Cas9 with a guide RNA to form a CRISPR/Cas9 complex that binds a specified DNA sequence
- Various formats for delivering these complexes in cells of all types
- Use of the CRISPR/Cas9 complex to cleave DNA (resulting in knock-outs, insertions or mutations)
- Use of mutated Cas9 to ‘nick’ DNA (in place of cleavage) or to bring an effector domain to a specified DNA sequence to regulate gene expression in a cell
- Compositions of guide RNAs in a variety of formats including various lengths, chemical modifications, and base compositions